TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Overall Response Rate (ORR) at Week 24 for CLL Participants
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Rate of Patients Reporting a Treatment Emergent Adverse Event (TEAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of patients with late grade 3 or higher gastrointestinal and/or genitourinary adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Safety assessed by clinical laboratory test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety assessed by 12-Lead ECG
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change from baseline in relative insulin response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: CD4+CD28null frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Response to Post-Product Use Questionnaires 1
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Tissue fibrosis, edema and exudation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of dasatinib permanent discontinuing patients
Endpoint domain: Adverse events/effects
Primary endpoint: daily warfarin dosing requirements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HRA discomfort scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Loco regional control
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Percent Change in Convulsive Seizure Frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Complete Resolution of Vaso-occlusive Events
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of Subjects With Serum 25-hydroxyvitamin D ≥30 ng/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean Percent Change From Baseline in Plasma Intact Parathyroid Hormone (iPTH)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Longitudinal trajectories of biological-fluid biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: FEV1pp
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in Young Mania Rating Scale score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in IRLS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Coximetry test result
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Feasibility of TORS
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Patency rate of venous stent
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: HbA1c as a measure of glycemic control
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percent Change From Baseline in Quadriceps Femoris Maximum Voluntary Isometric Contraction (MVIC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: abdominal and shoulder pain scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in urticaria activity scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adherence to fasting
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to virologic failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change From Baseline in Fasting Plasma Glucose at Day 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change From Baseline in Fasting Plasma Glucose at Day 28
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change From Baseline in Glucose Metabolism (Pre-meal and Postprandial Glucose), PPG iAUC 5h, at Day 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change From Baseline in Glucose Metabolism (Pre-meal and Postprandial Glucose), PPG iAUC 5h, at Day 28
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Efficacy of Er:YAG AFL-PDT vs MAL-PDT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of Overall Success
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Clinical signs of delayed cerebral ischemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Degree of change in AMH, FSH, and E2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Degree of recovery of AMH, FSH, and E2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Responsiveness to hypertonic saline cough challenge
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in stroke volume/end systolic volume (SV/ESV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Length of weaning
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacokinetics (PK) profile of MOD-4023
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of subjects achieving ACR20 response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Confusion assessment method (CAM) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Upper Limb Function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hand Function in Children
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Upper Extremity Function Rating
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Subjects Needing to Switch Comparator Drugs
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of Subjects Developing Any Treatment-related Grade 3-4 Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: AUC (0-48 Hours)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax After Subcutaneous Injection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: IL-17 levels in gingival crevicular fluid
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: IL-17 levels in saliva
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: IL-35 levels in gingival crevicular fluid
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: IL-35 levels in saliva
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Sternotomy pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Drain pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Leg incision pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: All Cause Hospital Mortality
Endpoint domain: Mortality/survival
Primary endpoint: Response rates in preventing HAE attacks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: accuracy of planned and actual result
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of pediatric trauma and fractures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of asynchronies during nava mode
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Osseous healing of chronic apical periodontitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Markers of coagulation (D-dimer)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Proportion of Infants Hospitalized for Lower Respiratory Tract Infection (LRTI) With a Positive RSV Diagnostic Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Proportion of Infants Who Died From a Confirmed RSV Infection
Endpoint domain: Mortality/survival
Primary endpoint: Ability to establish organoid cultures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Health related quality of life (HR-QoL)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Progression-free survival rate at six months
Endpoint domain: Mortality/survival
Primary endpoint: Change in Modified Ultrasound-7 Joint (mUS7) Sumscore
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cognitive Function (NeuroTracker)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Cognitive Function (The Trail Making Test)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Cognitive Function (the Wechsler Adult Scale-Revised Digit Span test)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in α4β2* nAChR binding potential
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MedDietScore
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in vitality score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: ∆g of Breakfast With/Without Pomelo
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: AUCs With/Without Pomelo
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Occurrence of oozing/bleeding at the staple line
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Occurrence of surgical interventions required to achieve hemostasis at the staple line
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Bone level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sustained virological response rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Sickle red cell response to epinephrine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Postoperative complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Oral microbial colonization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adjudicated Incidence of Bleeding Events
Endpoint domain: Adverse events/effects
Primary endpoint: Percent of Subjects With Liver-related Laboratory Marked Abnormalities (MA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: IgG/IgM antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: I-FABP elevation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: System related adverse device effects
Endpoint domain: Adverse events/effects
Primary endpoint: Level of empowerment
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Changes in cycloplegic off-axial auto-refraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in aberration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in eyeball length
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cardiac fibrosis area
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Effectiveness of [(131)I]MIBG treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Specificity for malignant lung nodules
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 28 Days mortality
Endpoint domain: Mortality/survival
Primary endpoint: Requirement of supplemental oxygen support
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Adverse events during hospital stay
Endpoint domain: Adverse events/effects
Primary endpoint: Local Injection Site Reactogenicity
Endpoint domain: Adverse events/effects
Primary endpoint: Therapeutic cure rate of bacterial vaginosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Toddler Attachment Sort-45
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Nursing Child Assessment Satellite Training (NCAST) Teaching Scale
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Indicator of Parent-Child Interaction (IPCI)
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Brief Infant-Toddler Social Emotional Assessment
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Bayley Scales of Infant Development, 3rd Edition Screening Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients with negative prostate biopsy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Insertion times
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ventilation times
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pressure pain threshold over the upper trapezius muscles
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Time until patient request for pain medication
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Individual level stigma scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Increase in Beta-hydroxybutyrate level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Recurrence of cerebral venous sinus thrombosis, deep cerebral venous thrombosis and cortical vein thrombosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Rate of eligibility
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Rate of refusal
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Rate of adherence to the study protocol
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Rate of participation in follow-up
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Rate of dropout
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Patient satisfaction with the relaxation intervention
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Number of INH pills taken
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: response quality
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Family communication connectedness Index
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Diet plan recall directly after visit
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Activity plan recall directly after visit
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Number of seroma aspirations
Endpoint domain: Adverse events/effects
Primary endpoint: Grade 3 or greater genitourinary toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Grade 3 or greater gastrointestinal toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Mean Glucose Concentration Measured by CGM
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Participants With Hypoglycemic Events
Endpoint domain: Adverse events/effects
Primary endpoint: Physicians Global Assessment (PGA) of Change
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change of HOMA2-IR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: NOSE Responder Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Attenuation Ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recurrence of Ganglia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Concentration-Time Curve From Zero to Infinity [AUC(0-∞)]
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anti mutated citrullinated vimentin antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Anti cyclic citrullinated peptide antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Complete reform of renal function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Changes in echocardiography during exercise
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Overall pen preference
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Percent change in visceral fat area
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Maximal treadmill exercise test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Responders With Calcium Source at Week 52
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Responders With Calcium Source at End Of Treatment (EOT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Toxicokinetic parameters of lambda-cyhalothrin elimination
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent of stent struts covered by endothelium
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: TMS parameters of cortical excitation and inhibition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Traumatization
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: GVHD-free Survival
Endpoint domain: Mortality/survival
Primary endpoint: cannulation time for deep pancreatic duct cannulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: fluoroscopy time for deep pancreatic duct cannulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change in Intraocular Lens Calculation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change in Intraocular Lens Power Calculation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Appropriate size of uncuffed endotracheal tube
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Symptom score assessment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of patients with Dose limiting Toxicity (DLT)
Endpoint domain: Adverse events/effects
Primary endpoint: Timeliness of calls to clinic for adjustment in therapy
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Patient engagement evaluated through patient survey
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Improved percentage of LV pacing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Participation rate to screening colonoscopy
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of participants who develop type 2 diabetes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Time to development of type 2 diabetes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Effectiveness of Anastrozole therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Rate of detection of clinically relevant bacterial or viral pathogen (CRBV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change From Baseline in Tumor Immune Response Evaluated by IHC Analysis of Tumor Infiltrating Lymphocytes (TILs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change From Baseline in Interferon (IFN)-Gamma Secretion of Mononuclear Cells in Response to MUC1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change From Baseline in IFN-gamma Secretion of Mononuclear Cells in Response to Carcinoembryonic Antigen (CEA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Safety of BM extraction and stem cell joint infusion
Endpoint domain: Adverse events/effects
Primary endpoint: Body weight of study children
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Body mass index of study children
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Waist circumference of study children
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: All-Cause Hospitalizations
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Weight Gain in Grams Per Day
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Blood Oxygen Level Dependent (BOLD) Signal
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes